PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis

N Ruperto,Daniel J. Lovell,Katerina Jarosova,D. Nemcova,Veronika Vargová,Hartmut Michels,E. Chalom,N Ilowite,Carine Wouters,Hi Brunner,Kk Kracht,H Kupper,Edward H. Giannini,A. Martini,N. Mozaffarian

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis

2013

N Ruperto
Daniel J. Lovell
Katerina Jarosova
D. Nemcova
Veronika Vargová
Hartmut Michels
E. Chalom
N Ilowite
Carine Wouters
Hi Brunner
Kk Kracht
H Kupper
Edward H. Giannini
A. Martini
N. Mozaffarian

Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA patients (pts) when dosed every other week (eow) for up to 3 years [1], but the effect of ADA on growth is not known.

Keywords:

Arthritis
Rheumatology
Physical therapy
Adalimumab
Juvenile
Medicine
Internal medicine
every other week
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations